SNV4818 in Participants With Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

Key facts

Study ID

NCT06736704

Run by

Pikavation Therapeutics, Inc.

People needed

320

Starts

2025-02-20

Expected to finish

2027-06-01

Last updated by the study team

2026-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced or metastatic solid tumor with an activating PIK3CA mutation.
• Refractory to or intolerant of available therapies
• Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in blood.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

You may not qualify if…

• Diagnosis of a primary CNS malignancy
• Active brain metastases or carcinomatous meningitis
• Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
• Inadequate organ function
• Clinically significant ECG abnormalities, including QTcF ≥ 470 ms

Where it is running

• The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Thomas Jefferson University-Sidney Kimmel Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
• The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States (enrolling)
• Chris O'Brien Lifehouse — Camperdown, New South Wales, Australia (enrolling)
• Scientia Clinical Research — Randwick, New South Wales, Australia (enrolling)
• Monash Health — Clayton, Victoria, Australia (enrolling)
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia (enrolling)
• Linear Clinical Research — Nedlands, Western Australia, Australia (enrolling)
• The Ottawa Hospital Cancer Centre — Ottawa, Ontario, Canada (enrolling)
• University Health Network, Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.